Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post on X:
“ctDNA in CRC is prognostic, but there is no data showing that treatment initiated earlier based upon ctDNA positivity confers improved survival (or QOL). Earlier detection alone does not equal benefit.”
Michael Shusterman, GI Medical Oncologist at Perlmutter Cancer Center at NYU Langone Health, added:
“This 100%. I am not aware of a single predictive study demonstrating survival benefit with ctDNA to date. Also, despite BESPOKE findings, every ctDNA positive patients we have seen has had significant anxiety. We offer it as a prognostic tool, but long term role?”
